Beyond 1L EGFRm mNSCLC Management: Today’s Challenges, Tomorrow’s Approach

GRACE
A

Overcoming Resistance in EGFR+ NSCLC

By GRACE FEATURING Aakash Desai
By GRACE FEATURING Aakash Desai
201 views
January 31, 2023
0 Comments
Login to view comments. Click here to Login
11:22
UCLA Health

HERTHENA-Lung01 Study: Patritumab Deruxtecan as a HER3 Target in EGF…

Feat. A. Lisberg
13:17
Joshua Reuss

ADCs in Lung Cancer: A Transformative Therapeutic Class?

21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC

16:17
Timothy Burns

Non-TKI-Based Strategies for EGFR Common Mutations

20:28
OncoAlert

mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC

Feat. C. Aggarwal
20:43
GRACE

Newer Types of Treatment for Lung Cancer: ADCs and Bispecifics

Feat. L. Bazhenova
23:50
GRACE

Targeted Therapies in Lung Cancer 2023: EGFR Targeted Therapies in N…

Feat. I. Preeshagul
06:44
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "The Impact of PET-CT Brain MRI for Metasta…

Feat. W. Liang